Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth (CGC) announced an expansion of its medical cannabis portfolio in Australia, adding new product formats and formulations across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands.
The company introduced its first pastille and all-in-one vape formats in the market, alongside new oil products that include CBG and CBN and additional softgel options beyond isolate-based formulations. Two new flower SKUs were also added under the Twd. value range, which the company said responds to Australian prescribers’ and patients’ requests for more choice in formats and formulations.
Canopy Growth (Nasdaq: CGC) has mailed or provided online access to proxy materials and its fiscal 2026 annual report for the Annual General and Special Meeting on September 25, 2026 at 1:00 PM ET, to be held via live audio webcast at www.virtualshareholdermeeting.com/WEED2026.
Shareholders of record as of July 31, 2026 are eligible to vote and are urged to do so by 1:00 PM ET on September 23, 2026 to ensure their votes are counted and help meet Nasdaq’s 33 1/3% quorum requirement. Items up for vote include election of directors, appointment of MNP LLP as auditor, a discretionary share consolidation proposal, an advance notice by-law, omnibus incentive plan entitlements, and advisory votes on executive compensation and its frequency.
Canopy Growth (Nasdaq: CGC; TSX: WEED) announced that its Kincardine, Ontario cultivation facility has secured renewed EU Good Manufacturing Practice (EU GMP) certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg.
The renewed status allows Canopy Growth to continue supplying Canadian-grown medical cannabis flower from Kincardine to European markets. Kincardine serves as the anchor asset in the Company’s end-to-end EU GMP flower supply chain, linked to its second EU GMP facility in Sankt Leon-Rot, Germany. According to Canopy Growth, growing business momentum in Europe contributed to a 10% year-over-year increase in international cannabis net revenue in the first quarter of fiscal 2027.
Canopy Growth (Nasdaq: CGC) reported Q1 FY2027 net revenue of $81.2 million, up 13% year-over-year, with cannabis revenue of $65.1 million (+14%). Segment growth included 22% in Canada medical, 10% in Canada adult-use, 10% in international cannabis, and 6% at Storz & Bickel.
Consolidated gross margin rose to 27%, while adjusted gross margin reached 31% versus 25% a year earlier. Adjusted EBITDA loss narrowed to $3.2 million, a 59% improvement, and net loss shrank by 68% to $14.6 million. However, free cash outflow widened to $25.7 million from $11.6 million. Cash and cash equivalents were $336.6 million and total debt (current and long term) was about $240.2 million at June 30, 2026.
Canopy Growth highlighted integration benefits from the MTL Cannabis acquisition, stronger market positions in Canadian adult-use, and the launch of a refreshed corporate identity aligned with its cannabis-focused strategy.
Canopy Growth (Nasdaq: CGC, TSX: WEED) will release its financial results for the first quarter of fiscal 2027, covering the period ended June 30, 2026, before markets open on August 7, 2026.
The company will host a live audio webcast with CEO Luc Mongeau and CFO Tom Stewart on August 7, 2026 at 10:00 AM ET, accessible at the provided URL. A replay will be available at the same link until 11:59 PM ET on November 5, 2026.
Canopy Growth (Nasdaq: CGC; TSX: WEED) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, held August 11–13, 2026. CEO Luc Mongeau is scheduled to present on Tuesday, August 11, 2026 at 12:00 p.m., with the session available via live webcast and archived online for 180 days. Institutional investors at the conference may also request one-on-one meetings with Canopy Growth through their Canaccord Genuity sales representative.
Canopy Growth (Nasdaq: CGC) reported Q4 FY2026 net revenue of $71.2M, up 10% year-over-year, and FY2026 net revenue of $284.6M, up 6%. Cannabis net revenue rose 20% in Q4 and 15% for FY2026, led by 27% growth in Canada medical and 20% growth in Canada adult-use.
International cannabis revenue grew 68% in Q4 but fell 7% for the year. FY2026 consolidated gross margin declined to 24%. Net loss from continuing operations narrowed 49%, adjusted EBITDA loss improved to $20.2M, and free cash outflow improved to $69.1M. Net cash ended at $131.3M after acquiring MTL Cannabis. The company targets positive adjusted EBITDA in FY2027.
Canopy Growth (Nasdaq: CGC) announced that Claybourne’s Frosted Flyers Variety Pack won “Best Infused Pre-Roll” at the 2026 Grow Up Awards in Toronto.
The company is expanding Frosted Flyers in Canada with three new 8-pack variety formats and a new bundle pack rolling out nationwide for summer.
Canopy Growth (Nasdaq: CGC) is relaunching its Tweed brand in Germany’s medical cannabis market, introducing three MTL-developed strains: Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes. Up to five more strains are planned for June 2026.
The move is the first international product release following the MTL acquisition. Canopy Growth also received a management cease trade order from the Ontario Securities Commission on May 28, 2026, and plans to refile affected financial statements in a comprehensive Form 10-K by June 15, 2026.
Canopy Growth (Nasdaq: CGC) will release its fourth quarter and fiscal year 2026 results, along with restated 2024 and 2025 figures, before markets open on June 15, 2026.
The company identified a non-cash warrant classification error and plans a refiling that, according to management, is not expected to impact revenue, cash flow, key metrics, liquidity, or debt covenants. Canopy has applied for a management cease trade order until the refiling is complete and will host an investor webcast on June 15, 2026 at 10:00 AM ET.